HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients

• DOI: 10.3389/fimmu.2021.723196
• Publication Date: 2021-08-23T05:25:41Z
• Authors: Óscar Brochado-Kith; Isidoro Martínez; Juan Berenguer; Juan González-García; Sergio Salgüero; Daniel Sepúlveda-...; Cristina Díez; Víctor Hontañón; Luis Ibañez-Saman...; Leire Pérez-Latorre; Amanda Fernández-...; María Ángeles Jim...; Salvador Resino
• Keywords: Hepatitis C; Liver disease

Hepatitis C virus (HCV) cure after all-oral direct-acting antiviral (DAA) therapy greatly improves the liver and immune system. We aimed to assess impact of this HCV clearance on system-related markers in plasma gene expression profile human immunodeficiency (HIV)/HCV-coinfected patients with advanced cirrhosis. performed a prospective study 33 HIV/HCV-coinfected at baseline 36 weeks sustained virological response. Gene was evaluated by RNA-seq analysis peripheral blood mononuclear cells (PBMCs) biomarkers multiplex immunoassays. found decrease (PD1, PDL1, CXCL10, CXCL8, IL12p70, IL10, TGFβ) disease (stiffness measurement (LSM), hepatic venous pressure gradient (HVPG), transaminases, among others). Furthermore, decreased levels PD1 were associated reduced LSM values. also two upregulated ( HAS1 IRG1 ) 15 downregulated CXCL11, CCL8, CCL7, CCL2, ADARB2, RRAD, MX1, SIGLEC1, IFI44L, IFI44, IFI27, IFI6, IFIT3, IFIT1B , IFIT1 genes end follow-up, all interferon-stimulated (ISGs) grouped into four pathways (“cytokine-cytokine receptor interaction”, “viral protein interaction cytokine receptor”, “chemokine signaling pathway”, “hepatitis C”). Additionally, most these ISGs significantly related HVPG In conclusion, advanced-HCV-related cirrhosis who eradicated following DAA exhibited an improvement significant antiviral/inflammatory response, particularly several chemokines ISGs.